Nurix Therapeutics
Update in progressNRIX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nurix Therapeutics is a clinical‑stage biopharmaceutical company developing small molecules and antibodies for cancer, inflammatory diseases, and related conditions. Its programs include NX-5948 (BTK degrader) in Phase 2, NX-2127 (BTK degrader) in Phase 1, NX-1607 (CBL‑B inhibitor) in Phase 1, and NX‑0479/GS‑6791 (IRAK4 degrader) for inflammatory diseases. It collaborates with Gilead, Sanofi, and Pfizer. Founded in 2009 as Nurix Inc., renamed in 2018, based in Brisbane, CA.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.26
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!